Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease

References

• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr. 2008;79:368–376.
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010;25:1646–1651.
   PubMed Web of Science ®Google Scholar
• Poewe W, Antonini A, Zijlmans JC, et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging. 2010;5:229–238.
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977;1:345–349.
   PubMed Web of Science ®Google Scholar
• Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol. 2006;147:S287–S296.
   PubMed Web of Science ®Google Scholar
• Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:1589–1598.
   PubMed Web of Science ®Google Scholar
• Calne DB. Selegiline in Parkinson's disease. BMJ. 1995;311:1583–1584.
   PubMedGoogle Scholar
• Degli Esposti L, Piccinni C, Sangiorgi D, et al. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurol Sci. 2016;37:227–234.
   PubMed Web of Science ®Google Scholar
• Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp Neurol. 2011;20:1–7.
   Google Scholar
• DeMaagd G, Philip A. Parkinson's disease and its management: Part 3: nondopaminergic and nonpharmacological treatment options. Pharm Ther. 2015;40:668.
   Google Scholar
• Lew MF. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Rev Neurother. 2005;5:705–712.
   PubMedGoogle Scholar
• Frampton JE, Plosker GL. Selegiline transdermal system in the treatment of major depressive disorder. Drugs. 2007;67:257–265.
   PubMed Web of Science ®Google Scholar
• Hidestrand M, Oscarson M, Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001;29:1480–1484.
   PubMed Web of Science ®Google Scholar
• Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther. 1996;3:688–698.
   PubMedGoogle Scholar
• Al-Dhubiab BE, Nair AB, Kumria R, et al. Development and evaluation of buccal films impregnated with selegiline-loaded nanospheres. Drug Deliv. 2016;23:2154–2162.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437–449.
   PubMed Web of Science ®Google Scholar
• Bicker J, Alves G, Fortuna A, et al. Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur J Pharm Biopharm. 2014;87:409–432.
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94:1187–1195.
   PubMed Web of Science ®Google Scholar
• Misra A, Jogani V, Jinturkar K, et al. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul. 2008;2:25–40.
   PubMedGoogle Scholar
• Vyas TK, Shahiwala A, Marathe S, et al. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005;2:165–175.
   PubMedGoogle Scholar
• Kapoor R, Turjanski N, Frankel J, et al. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatr. 1990;53:1015.
   PubMed Web of Science ®Google Scholar
• Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res. 2000;17:978–984.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Roeytenberg A, Martinez PM, et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharm Exp Ther. 2009;330:679–686.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, et al. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv. 2013;20:47–56.
   PubMed Web of Science ®Google Scholar
• Marttin E, Schipper NG, Verhoef JC, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29:13–38.
   PubMed Web of Science ®Google Scholar
• Majithiya RJ, Ghosh PK, Umrethia ML, et al. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech. 2006;7:E80–E86.
   Web of Science ®Google Scholar
• Swamy NG, Abbas Z. Mucoadhesive in situ gels as nasal drug delivery systems: an overview. Asian J Pharm Sci. 2012;7:168–180.
   Google Scholar
• Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57:1640–1665.
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Hamed AY, Mahrous GM, et al. Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Dev Ind Pharm. 2009;35:352–362.
   PubMed Web of Science ®Google Scholar
• Schmolka IR. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6:571–582.
   PubMed Web of Science ®Google Scholar
• Krishnaiah YSR, Jayaram B, Rama B, et al. Reverse-phase HPLC method for the estimation of selegiline hydrochloride in pharmaceutical dosage forms. Asian J Chem. 2003;15:1291–1296.
   Google Scholar
• Angeline MS, Chaterjee P, Anand K, et al. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience. 2012;220:291–301.
   PubMed Web of Science ®Google Scholar
• Nehru B, Verma R, Khanna P, et al. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res. 2008;1201:122–127.
   PubMed Web of Science ®Google Scholar
• Wadenberg ML, Soliman A, VanderSpek SC, et al. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 2001;25:633–641.
   PubMed Web of Science ®Google Scholar
• Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15:5372–5378.
   PubMed Web of Science ®Google Scholar
• Yeomanson KB, Billett EE. An enzyme immunoassay for the measurement of human monoamine oxidase B protein. Biochim Biophys Acta. 1992;1116:261–268.
   PubMedGoogle Scholar
• Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem. 1952;195:133–140.
   PubMed Web of Science ®Google Scholar
• Jollow DJ, Mitchell JR, Zampaglione NA, et al. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3, 4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 1974;11:151–169.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Grossiord JL, Agnely F, et al. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23:2709–2728.
   PubMed Web of Science ®Google Scholar
• Ur-Rehman T, Tavelin S, Gröbner G. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm. 2011;409:19–29.
   PubMed Web of Science ®Google Scholar
• Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm. 2010;75:186–193.
   PubMed Web of Science ®Google Scholar
• Zaki NM, Awad GA, Mortada ND, et al. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32:296–307.
   PubMed Web of Science ®Google Scholar
• Sadeghi AM, Dorkoosh FA, Avadi MR, et al. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm. 2008;70:270–278.
   PubMed Web of Science ®Google Scholar
• Uversky VN. Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004;318:225–241.
   PubMed Web of Science ®Google Scholar
• Sanberg PR, Pisa M, Fibiger HC. Kainic acid injections in the striatum alter the cataleptic and locomotor effects of drugs influencing dopaminergic and cholinergic systems. Eur J Pharmacol. 1981;74:347–357.
   PubMed Web of Science ®Google Scholar
• Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136:317–324.
   PubMed Web of Science ®Google Scholar
• Roghani M, Behzadi G, Baluchnejadmojarad T. Efficacy of elevated body swing test in the early model of Parkinson's disease in rat. Physiol Behav. 2002;76:507–510.
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci. 2006;248:266–270.
   PubMed Web of Science ®Google Scholar
• Knoll J. The pharmacological basis of the beneficial effects of (-) deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J Neural Transm Supplementum. 1992;40:69–91.
   Google Scholar
• Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–435.
   PubMed Web of Science ®Google Scholar
• Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295–309.
   PubMed Web of Science ®Google Scholar
• Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115:193–203.
   PubMed Web of Science ®Google Scholar
• Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res. 2005;134:109–118.
   PubMedGoogle Scholar
• Tada-Oikawa S, Hiraku Y, Kawanishi M, et al. Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis. Life Sci. 2003;73:3277–3288.
   PubMed Web of Science ®Google Scholar
• Carrillo MC, Kanai S, Nokubo M, et al. (−) (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol. 1992;116:286–294.
   PubMed Web of Science ®Google Scholar
• Browne RW, Armstrong D. Reduced glutathione and glutathione disulfide. Free Radic Antioxid Protocols. 1998;108:347–352.
   Google Scholar
• Kourie JI. Prion channel proteins and their role in vacuolation and neurodegenerative diseases. Eur Biophys J. 2002;31:409–416.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord. 2013;28:31–40.
   PubMed Web of Science ®Google Scholar
• Jortner BS. Neuropathological assessment in acute neurotoxic states. The "dark" neuron. J Med CBR Def 2005;3:1–5.
   Google Scholar